This document announces a short course on structure-based drug design for epigenetic targets to be held on June 19, 2013 at the Revere Hotel in Boston prior to a larger conference. The course will review how structural biology has contributed to the discovery of small molecule modulators of epigenetic targets. It will focus on emerging targets such as bromodomains, methyltransferases, and lysine demethylases. Attendees can register online, by phone, or via email.

1. Structure-Based Drug Design for Epigenetic Targets
***** A Short Course Announcement *****
with Johnathan R. Whetstine, Ph.D., Assistant Professor of Medicine, Harvard
Medical School & Philip Fallon, Ph.D., Senior Medicinal Chemist, Domainex Ltd.
June 19, 2013 – The Revere Hotel – Boston, MA
Epigenetic processes are the focus of intense interest, and the families of proteins that mediate
epigenetic signalling are a highly promising source of new drug targets. Tackling this emerging
field of novel drug targets is not without its challenges. This workshop will review the contribution
that structural biology has made to the discovery of small molecule modulators. Structural
information can be invaluable in determining the druggability of potential targets, and in enabling
more efficient identification of hit molecules. Structural information can also guide the design of
compounds with improved affinity for the target, or selectivity versus other targets. This
introductory course on drug design for epigenetic targets will focus especially on emerging targets
such as bromodomain (readers), methyltransferase (writers) and lysine demethylase (erasers).
This course will be held from 9:00 am – 12:00 pm prior to the start of CHI’s Structure-
Based Drug Design conference (June 19-21).
WAYS TO REGISTER:
Online: https://chidb.com/register/2013/sbd/reg.asp
Call: 781-972-5400
Email: reg@healthtech.com
http://www.healthtech.com/sbd